Hawaii may be seeing the belated effect of large gatherings held over the past few weeks, but Department of Health officials said Friday there is no direct evidence as of yet.
Memorial Day weekend and the recent protest against racial injustice that attracted 10,000 people to Hawaiis State Capitol are likely among the reasons why Hawaii is seeing a slight uptick in new COVID-19 cases, Lt. Gov. Josh Green said Friday.
This is the time to recommit ourselves to wear masks and social distancing, Green said. Were still waiting to see the effects of the nonviolent protests, which happened about seven days ago. Id expect were going to see a small surge because of close communication and some spread from large gatherings.
I was proud of our people from a freedom of speech standpoint. But from an infectious disease standpoint, I am a little worried, he added.
Lt. Gov. Josh Green said he anticipates some cases to arise after the protests held last weekend.
Cory Lum/Civil Beat
Fifteen new cases were confirmed on Friday, the largest daily increase seen in the islands since mid-April. Elsewhere in the nation, Memorial Day festivities have been attributed to upticks in cases.
Bruce Anderson, the director of the Hawaii Department of Health, said at a press conference Friday there is no evidence to date about coronavirus cases associated directly with the protests or around Memorial Day.
Other states have seen increases associated with that time frame, he said, but at the same time other states are opening up business, theres a lot more travel and people are getting out and about and theres more opportunity for contact.
Most of the gatherings that we were monitoring here were relatively small. People were respecting each other. No cases that I know of are associated with the protest.
One trend in Hawaiis recent cases is becoming more clear: many diagnoses of COVID-19 have been among families. In mid-May, one cluster of infections involved seven people in an extended Oahu family who lived in public housing.A string of cases in Kailua-Kona on the Big Island last month was later attributed to restaurant employees transmitting the virus to family and household members.
Ten of the 15 infections confirmed Friday were found as a result of contact tracing in one Waipahu household, Anderson told Civil Beat. In total, six children and four adults were found to be infected when an investigation was launched after one original case was confirmed.
Now there are 11 people in one household who were confirmed cases, Anderson said. Fourteen people were living in the home with two bedrooms. Its a very crowded situation, where its practically impossible to do physical distancing.
These types of cases are a reflection of the states high prevalence of multi-generational housing, both state officials said.
To address the issue, Anderson said that DOH public health nurses have been conducting outreach across all islands as a public education effort. In cases where they see a high risk of transmission, they have swabbed adults and children to test them for the virus. Members of the Hawaii National Guard have also assisted in specimen collection in recent weeks, he said.
Department of Health Director Bruce Anderson said public health outreach workers have conducted an educational outreach effort, particularly in areas known to have extended family and multi-generational housing.
Cory Lum/Civil Beat
The teams of outreach workers, which include nurses, interpreters, epidemiologists and other staff from the DOH Division of Disease Control and Prevention along with the Hawaii National Guard, have knocked on doors to provide guidance and also assess high risk living situations.
Yesterday, for example, Anderson said he received negative results of swabs taken from more than a hundred people who lived in a neighborhood near Sand Island.
The Department of Health is focusing on low-income areas where multi-generational living is often the norm, Anderson said. Hawaii has twice the national rate of multi-generational households, according to estimates by the American Community Survey.
We obviously want to bring the rates of disease down as much as we can in these areas, he said. We see this as a long-term focus area.
Green said testing will be an important component of reopening the state to visitors, because of the many people who work in the hospitality industry.
He is proposing Hawaii adopt a mandatory COVID-19 test for incoming trans-Pacific travelers, similar to a new Alaska policy.
Our multi-generational households could increase serious illness if our working class citizens end up spreading it to their parents or grandparents, Green said. Its the reason that Hawaii has to go the extra mile to prevent cases from coming into the state.
Sign Up
Sorry. That's an invalid e-mail.
Thanks! We'll send you a confirmation e-mail shortly.
So much is still unknown about COVID-19. Why do some healthy people fall severely ill, while others may not show symptoms? Two Hawaii researchers are hoping to find out.
Alika Maunakea, a biomedical researcher at the University of Hawaii John A. Burns School of Medicine and Ruben Juarez, a mathematical economist at the University of Hawaii Economic Research Organization, are looking to track the recovery of Hawaii COVID-19 patients who have cleared quarantine and can donate blood at the medical school.
Maunakea and Juarez want to explore what the human immune system says about COVID-19 and find more clues about what can halt its progression. Ultimately, they hope to identify ways to prevent patients from falling severely ill, and understand underlying disparities not only in infection rates but also severity and recovery of COVID-19, said Maunakea.
We want to collect some baseline information on recovering individuals because thats something we dont really have an understanding of right now, especially in Hawaii, he said.
Local researchers want to use antibody testing to understand immune response to COVID-19. The results, they say, would ideally help vulnerable populations in preventing severe health issues caused by the virus.
Hawaii Pacific Health
Those who are invited to participate are people who have tested positive for COVID-19 within the past 60 days and who are cleared from quarantine. Participants will be asked to donate a small blood sample once a week for six weeks at the UH medical school.
A coronavirus infection can not only trigger fever, coughing and shortness of breath, but gastro-intestinal problems, as well. In some cases the body may overreact in its response, which can lead to worst case scenarios: pneumonia, severe respiratory complications, kidney failure or death.
Theres a lot of variability in peoples ability to recover. Several risk factors have crystallized during the first six months of the pandemic: elderly people and those with preexisting medical conditions have a higher risk for complications. Research is also underway about why the disease has taken a higher toll on some people based on sex or ethnicity, often tied to socioeconomic factors.
By examining the development of antibodies, Maunakea and Juarez want to track patients immune response and use the science of immune health to address COVID-19 disparities.
During the course of infection, symptoms can appear belatedly. But once those symptoms subside, there is still vital information provided by antibodies.
Antibody tests could yield more information about people who had asymptomatic cases, they say.
Were looking at how individuals recover from the infection, because we dont really understand to what degree of viral antibodies they may have produced and what their inflammatory response may look like during the course of infection, said Maunakea.
There are certain biological pathways, such as microbiome composition, that can either lead to resilience against the virus or contribute to complications, he said.
The goal is to improve ways to target which patient populations will need most help, Juarez said.
What are the diseases like diabetes that we should be paying more attention to? he said. If were able to design this and be able to get the results on the interactions on the microbiome with the disease it could potentially tell you or prescribe things you need to target, things like diet, or nutrition.
The researchers will share what they find with others across the U.S. working on similar studies. Eventually, as Hawaii reopens its doors to trans-Pacific visitors, Juarez says he hopes the research will assist state lawmakers with policy decisions.
This week, Gov. David Ige said COVID-19 testing is under discussion as a possible way to vet travelers arriving in Hawaii. Juarez says serological or blood testing could help in tandem with their research, since it can provide a historical picture of a patients possible immunity.
This can help us understand what serological testing could be done in an appropriate way, Juarez said.
More research is being conducted at the medical school.
Researchers there announced Friday they will conduct the states first outpatient clinical trial in hopes of finding a COVID-19 treatment. Theyre searching for 40 adults with active infections to participate.
Dr. Cecilia Shikuma, Professor of Medicine at JABSOM and the lead investigator for this study, said research patients will be placed on either a placebo (sugar pill) or telmisartan, a blood pressure control medication.
We hope to find preliminary evidence that taking the drug will also prevent much of the harmful effects of the virus, she said. It is an advantage that telmisartan is already FDA approved and much of the safety concerns of this drug is already known.
Sign Up
Sorry. That's an invalid e-mail.
Thanks! We'll send you a confirmation e-mail shortly.
As California reopened another large sector of its businesses Friday, the number of coronavirus cases continued on its upward trajectory and the death toll neared 5,000.
The state recorded its largest one-day increase in new cases Thursday, logging a total of 3,620 new infections and 79 additional deaths.
Los Angeles County accounted for nearly half of the increase. Public health officials reported nearly 1,850 new cases Thursday the largest one-day increase since the pandemic began and 50 related deaths. Of the new cases, 600 were from a backlog of test results, officials said.
L.A. County has now recorded more than 68,000 cases of the virus, almost half of the states case count of more than 143,000. The cumulative death toll in L.A. County 2,818 represents 57% of the states fatalities, despite the county being home to one-quarter of Californias population.
The continued rise comes as L.A. County took another step toward easing stay-at-home rules put in place to slow the virus spread. Friday marked the first day that gyms, fitness facilities, museums, swimming pools and hotels for leisure travel were permitted to reopen, and music, film and television production was allowed to resume.
Officials have always expected an increase in the number of cases as the strictest version of the stay-at-home order was gradually lifted.
The question now is whether COVID-19 will require the hospitalization of a moderate number of people, which the hospital system can handle, or grow into a surge of severely ill patients that will overwhelm intensive care units. It can take two to four weeks before hospitals start seeing a surge in patients after theyve been infected.
Hospitalizations have continued to decline slightly, but the pace has slowed since last month.
The most recent three-day average of the daily number of hospitalized patients represented a decline of about 1%, according to the latest figures from the Public Health Departments dashboard of reopening metrics. In late May, the decline was hovering at 15% to 16%.
As of Thursday, 1,416 confirmed coronavirus patients were hospitalized, with 29% of them in intensive care.
Another unknown is whether the increase in is because more people are contracting the virus, or it is a result of increased testing thats enabling health professionals to identify cases that would have otherwise gone undetected.
For that reason, officials are keeping an eye on the positivity rate, which represents the proportion of people who have tested positive out of all those who have been tested. So far, that number continues to decline.
As of Thursday, 746,000 people in L.A. County had been tested and received their results, with about 8% testing positive. In late May, the county reported a positivity rate of 8.5%, and in late April, it was 14%.
Still, theres also evidence that the spread of the virus is rising.
Before the county began easing stay-at-home requirements last month, the effective transmission rate of the coronavirus was in a good spot: Every infected person on average was infecting fewer than one other person, said Dr. Christina Ghaly, L.A. Countys director of health services.
But last Friday, Ghaly announced that the transmission rate had risen above 1.
The increase showed up a little more than two weeks after L.A. County allowed many retail stores to open for pickup service.
The model predicts more firmly that the spread of COVID-19 in the Los Angeles County area is likely to increase gradually over time, Ghaly said.
Hospitalizations for COVID-19 continued to fall across the state over the past week, even in the parts of southern Maine that have continued to see significant numbers of people testing positive for the disease.
At Maine Medical Center, which has had nearly half of the states confirmed coronavirus inpatients through most of the crisis, the number of confirmed COVID-19 inpatients hovered at between eight and 11 over the week ending Thursday, down from a peak level of 35 hit on both April 7 and May 25. The inpatient count Tuesday and Wednesday was the lowest daily number there since March 22, at the beginning of the crisis.
At Portlands other major hospital, Mercy, the number of inpatients fell from five to zero during the period, down from five to eight the previous week and eight to 10 the week before that, which had been the busiest that hospital had experienced during the pandemic.
In Androscoggin County, hospitalizations have fortunately not been paralleling discouraging trends in new cases. The county saw a dramatic spike in new COVID-19 cases in mid-May going from a seven-day average of one case at the end of April to more than 15 on May 23 and over the past seven days has averaged a still-high nine cases a day, according to data from the Maine Center for Disease Control and Prevention.
Statewide, 29 people were hospitalized Thursday with COVID-19. Thats fewer than half of the 60 who were hospitalized with the disease just two weeks earlier.
Hospitalizations, when they occur, typically follow at least two weeks after exposure, but the countys two major hospitals have no seen a commiserate spike.
Central Maine Medical Center, however, averaged 1.7 COVID-19 inpatients a day over the past week and 0.7 patients a day the week before that. Lewistons other hospital, St. Marys, reporting for the first time, averaged 3.7 a day, roughly comparable to the week before, though an exact comparison could not be made because the older data included presumed COVID-19 cases, not just confirmed ones.
Dr. John Alexander, chief medical officer for CMMCs parent, Central Maine Health Care, said this is happening because testing expanded in May to include more younger and healthier people who are less likely to be hospitalized by the disease.
Because we had very limited testing capacity early on, we only wanted to test people who had a very high likelihood of both having the disease and having an adverse outcome, Alexander said. Now we are just testing exposures very widely.
Alexander also said the low levels of hospitalizations in the state are in large degree due to Mainers taking the disease seriously. As a state, we have understood and we have taken into action the guidance around masking, around social distancing and around essentially keeping each other safe, he said.
The data, for the week ending June 11, was collected directly from the hospitals by the Press Herald, which has been reporting the hospital-by-hospital trends weekly since April 18.
York Countys hospitals were also relatively quiet. Southern Maine Health Care Medical Center in Biddeford which has had the most pandemic inpatients overall after Maine Med averaged three COVID-19 inpatients a day for the week, down from 4.1 a day the week before. York Hospital in York had no COVID-19 inpatients for the second week running.
MaineGeneral in Augusta, the hospital which has had the fourth largest pandemic burden to date, fell to an average of one patient a day for the week, down from 3.1 patients the week before. Eastern Maine Medical Center in Bangor had no COVID-19 inpatients at all, and Mid Coast Hospital in Brunswick hasnt had such a patient since May 23.
Three smaller hospitals reported having a patient during the course of the week: Bridgton, Waldo in Belfast and Franklin Memorial in Farmington. The Press Heralds survey includes most of the states hospitals and accounts for the vast majority of the statewide hospitalizations reported by the Maine CDC each week.
In all cases, hospitalizations can end three ways: recovery, death, or transfer to another facility. The data does not include outpatients or inpatients who were suspected of having the virus but never tested.
Hospitalizations are a lagging indicator, because it typically takes two or three weeks after exposure for an acutely affected person to become sick enough to be admitted, but it is one metric that is not effected by how many people are tested.
Invalid username/password.
Please check your email to confirm and complete your registration.
Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.
Previous
Next
John Young, Pfizers chief business officer, was only about four minutes into a one-hour fireside chat at this years virtual BIO conference when he addressed a question thats been weighing on investors for several weeks now: If the company successfully develops a vaccine against COVID-19, what will the return on investment be?
When Pfizer began strategizing methods for addressing the pandemic back in January, we realized this is not a time to think about a typical ROI, Youngsaid. Frankly, the world needs a safe and effective vaccine, and the companys priority is to play our part in bringing forward vaccines and treatments that the world needs right now.
Pfizer has been working with Germany-based mRNA specialist BioNTech to develop a COVID-19 vaccine. The partners are now in clinical trials, assessing four variants of the vaccine. After testing the variants at different schedules and dose levels, they will select a vaccine candidate to move into larger trials.
RELATED: After Operation Warp Speed picks 5 finalists, experts question why some vaccines were left out
Pifzer is one of five finalists in Operation Warp Speed, the U.S. governments attempt to speed up the development of a COVID-19 vaccine. But unlike other contenders, it is not looking for federal funding to accelerate clinical development. Theres a reason for that, Young said at BIO.
We made an active decision not to seek government funding because we didn't want this to slow down our partnership with BioNTech and to slow the progress moving a vaccine construct into the clinic, Young said. Our focus was to move as quickly as possible and we really didn't want to spend a month negotiating with the U.S. government.
So how long will Pfizers development process take? Young was reluctant to make any hard predictions. Too few patients have been dosed in the clinical trials thus far, he said, and ultimately data should really drive the decisions that we make, along with regulators, as to which [candidate] has the potential to be the safest and most effective vaccine construct.
But Pfizer is thinking about how to tackle the challenge of manufacturing enough doses of a COVID-19 vaccine to meet the demandand investing plenty in that effort. The company said in May it would lean on its manufacturing sites in Michigan, Massachusetts and Missouri, as well as a fourth site in Belgium, to ramp up production of the vaccine.
RELATED: Pfizer plans to farm out manufacturing for some of its drugs to make way for COVID-19 vaccine
During the BIO chat, Young said Pfizer will handle the U.S. supply chain and BioNTech will develop a parallel supply chain for Europe and rest the world. Meanwhile, Pfizer will outsource production of some its other drugs to contractors to clear manufacturing space.
Despite its strong partner network, the manufacturing of a COVID-19 mRNA vaccine will be far from simple, Young said. Typically, Pfizer makes about 500 million vaccine doses per year, but this time around, the company has committed to make tens of millions of doses this year and hundreds of millions in 2021 if one of its vaccine candidates succeeds, he said. So we need to more than double down on our investments in our supply chain, and to make significant investments of capital, as well as investments in some very specialized raw materials.
Young emphasized that making an mRNA vaccine is a brand-new endeavor for the company. It involves combining nanoparticles with mRNA and using plasmids to produce the mRNA. We have not made one of those products before, so we really had to from scratch work with raw material suppliers and companies that make these very specialized products.
It all brought to mind that one pressing question: What will the ROI be for Pfizer? To answer that, the company would need to estimate its own costs, not to mention the price of the vaccineneither of which its ready to do, Young said.
Pfizer has done no modeling work to this point around the pricing, Young said, because were still in the process of figuring out where our supply chain is to know even what our cost of manufacturing is. So its really premature in our vaccine program to reach a point of view on pricing.
RELATED:Analysts to Gilead CEO: What's your plan to monetize remdesivir?
The controversy over drug pricing continues to be a thorn in the side of the pharma industry, even amid thepandemic. Pfizer is well aware of the need to balance the need for an affordable COVID-19 vaccine with the demand from investors for ROIand the potential for its actions to help repair the industrys image, Young said.
We really need effective vaccines to get back to normal economic activity, Young said. So I hope, if we're successful in that mission the perception of our industry will reflect the efforts that we've made.
Third of Americans Say They Won't Get a COVID-19 Vaccine, with Black Americans the Most Skeptical Newsweek
WASHINGTON--(BUSINESS WIRE)--The Milken Institute, the nonprofit, nonpartisan think tank, and First Person, a San Francisco design and storytelling company, together tell the urgent story of the global race for a COVID-19 vaccine in a newly released interactive experience at: https://www.covid-19vaccinetracker.org/.
Developed by First Person, the web-based tool is the culmination of a nearly three-month long effort tracking treatment and vaccines candidates for COVID-19 undertaken by FasterCures, a center of Milken Institute. When it first launched, FasterCures identified 38 vaccine candidates. As of today, there are 161 vaccines in development, with 10 in clinical trials.
Developing a safe vaccine that can be widely accessed is both necessary and extraordinarily complex, said Esther Krofah, Executive Director at FasterCures. We are thrilled that First Person has been able to bring our comprehensive vaccine tracker to life in a way that educates the public and gives the medical research community a new tool to better understand the race toward a COVID-19 vaccine.
The interactive platform is updated regularly and takes the viewer through a narrative including:
"Our intent with this project was to answer the question of how long it would take to develop a COVID-19 vaccine, said Drew Fiero President and CEO of First Person. The comprehensive, neutral, and consistently updated data from FasterCures allowed us to leverage our storytelling capabilities to do just that through a visually compelling, interactive experience.
Compiled from more than 30 publicly available data sources, the COVID-19 Treatment and Vaccine Tracker is updated daily by FasterCures. The nonprofit welcomes input on new treatments and vaccines in development. Please email COVID19@milkeninstitute.org with tips.
About FasterCures
FasterCures, a center of the Milken Institute, is working to build a system that is effective, efficient, and driven by a clear vision: patient needs above all else. We believe that transformative and life-saving science should be fully realized and deliver better treatments to the people who need them.
About the Milken Institute
The Milken Institute is a nonprofit, nonpartisan think tank that helps people build meaningful lives, in which they can experience health and well-being, pursue effective education and gainful employment, and access the resources required to create ever-expanding opportunities for themselves and their broader communities. For more information, visit www.milkeninstitute.org
About First Person
First Person is a San Francisco design and storytelling company. We combine brilliant ideas with business insight to develop stories that leverage design and technology to deliver lasting value. The result is engaging media that informs, surprises and delights. For more information, visit www.firstperson.is
It wont be enough to find a vaccine that works against COVID-19. Scientists will then need to quickly make enough vaccine for hundreds of millions perhaps billions of people.
One San Diego biotechs solution to this manufacturing challenge? A vaccine that makes more of itself.
TriLink Biotechnologies is working with researchers at Imperial College London to test such a vaccine in a trial slated to begin in mid-June. If successful, the approach could help get a COVID-19 vaccine to a wide swath of the population quickly, says Anton McCaffrey, TriLinks director of emerging science and innovation.
Right now, everybody wants to go at warp speed, McCaffrey said. You need to know that you can make (a vaccine) at the scale thats required to vaccinate a substantial part of the population.TriLinks vaccine uses genes that viruses normally rely on to copy their genetic material. Only this time, those genes help copy a vaccine that focuses the immune systems attention on the surface of the novel coronavirus. After copying itself over the course of a couple weeks, the vaccine would eventually be cleared from a persons system, according to McCaffrey.
The viral genes that allow the vaccine to copy itself also make it larger and trickier to produce, but scientists wouldnt need to make as much. The company estimates that the approach reduces the amount of vaccine each person would need by 25- to 50-fold.
Because a self-replicating vaccine copies itself in the same way that a virus does, it would set off the same alarm bells triggered by infection. That could be a good thing, McCaffrey says, as an antiviral response would lead to a stronger immune counterattack.
That will need to be shown by clinical trials. Imperial College researchers will begin a Phase 1 clinical trial to test the vaccines safety in mid-June. If that goes well, UK scientists will run a larger trial testing whether the vaccine protects against COVID-19.
TriLink can make enough vaccine for the clinical trials. But McCaffrey says that it would need to build new facilities or license out its technology to make enough vaccine for global use.
TriLink Biotechnologies employs about 200 people and was founded in San Diego in 1996.
San Diego biotech Arcturus Therapeutics is exploring a similar COVID-19 vaccine strategy in partnership with Singapores national health authority.
DUBLIN--(BUSINESS WIRE)--The "COVID-19 Vaccine Development News - Bundle" newsletter has been added to ResearchAndMarkets.com's offering.
The COVID-19 Vaccine Development News Bundle includes the following:
1. Daily Report: COVID-19 Vaccine Development News
Offers five multiple time-zones updates, daily, for 20+ global news each related to COVID-19 Vaccine Development, comprehensively compiled and curated from global as well as regional and local news media.
Key features:
2. COVID-19 Vaccine Development News: Weekly Summary
50+ news summaries of the week relevant to COVID-19 vaccine development for global companies, research institutes, academia, hospitals/healthcare systems and organizations rounded up and summarized succinctly to present a complete overview of the current happenings worldwide here.
Key features:
3. COVID-19 Monthly Synthesis: Vaccine Development
Every month, progress related to COVID-19 vaccine development news from all over the world is monitored and synthesized to reflect the prevailing trends and directions in vaccine development.
Key features:
For more information about this newsletter visit https://www.researchandmarkets.com/r/l07sb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MADISON, Wis. (WBAY) - Wisconsin's coronavirus case numbers are back in familiar territory Wednesday after a record low for the percentage of positive test results the day before.
The state received results of 10,472 tests and 2.72% of them were positive, which is in line with the percentage of positive tests for the past week but down from the 5 to 6% averages seen in May.
The testing identified 285 patients carrying the coronavirus.
The state reported 10 deaths, including one each in Calumet, Sheboygan and Winnebago counties. Deaths were also reported in Dane (1), Jefferson (1) and Milwaukee (5) counties.
After the state's report came out, the Appleton Health Department reported the death of a Calumet County resident in the city. The patient was in their 60's. It was the city's fourth COVID-19 related death and will likely appear in the state numbers in the next day or two.
Winnebago County, which has become a local hotspot for the coronavirus, identified 26 new patients in this latest state report. That's at least twice as many cases as any other county in this 24-hour period except Milwaukee County. Winnebago County health officials link the increase to gatherings of young adults once the safer-at-home orders were lifted (see related story).
County-by-county case numbers appear below.
Statewide, people in their 20s account for 19% of confirmed coronavirus cases, more than any other age group. There are 4,008 cases. However, they only account for 4% of hospitalizations for COVID-19. Only children and teens have a lower percentage.
The state has seen nearly 3,000 patients (2,943) hospitalized for treatment of COVID-19 since the virus reached the state. That's 39 more than Tuesday.
There are currently 328 patients hospitalized for COVID-19, with 114 of them in intensive care. Another 190 people who are hospitalized are waiting for test results.
68% of people who tested positive are considered recovered, which the state defines as 30 days since the onset of symptoms or diagnosis, or having the absence of symptoms or their release from isolation medically documented.
County case numbersCounties with new cases and/or deaths are in bold.
WisconsinAdams - 6 cases (1 death)Ashland - 3 casesBarron - 21 cases (+1)Bayfield - 3 cases (1 death)Brown - 2,405 cases (+7) (38 deaths)Buffalo - 6 cases (2 death)Burnett - 1 cases (1 death)Calumet - 81 cases (2 deaths) (+1)Chippewa - 60 cases (+1)Clark - 45 cases (4 deaths)Columbia - 49 cases (+2) (1 death)Crawford - 26 casesDane - 884 cases (+13) (31 deaths) (+1)Dodge - 410 cases (+4) (4 deaths)Door - 39 cases (3 deaths)Douglas - 20 casesDunn - 29 casesEau Claire - 126 cases (+2)Florence - 2 casesFond du Lac - 247 cases (+6) (6 deaths)Forest - 34 cases (2 deaths)Grant - 99 cases (12 deaths)Green - 71 casesGreen Lake - 23 casesIowa - 16 casesIron - 2 cases (1 death)Jackson - 20 cases (+1) (1 death)Jefferson - 138 cases (+4) (4 deaths) (+1)Juneau 23 cases (1 death)Kenosha - 1,308 cases (+13) (36 deaths)Kewaunee - 37 cases (1 death)La Crosse - 81 cases (+4)Lafayette - 36 cases (+1)Langlade - 5 casesLincoln - 7 casesManitowoc - 40 cases (1 death)Marathon - 69 cases (+3) (1 death)Marinette - 37 cases (3 deaths)Marquette - 7 cases (+1) (1 death)Menominee - 3 casesMilwaukee 8,973 cases (+123) (336 deaths) (+5)Monroe - 23 cases (+4) (1 death)Oconto - 42 casesOneida - 13 casesOutagamie - 294 cases (+5) (8 deaths)Ozaukee - 185 cases (+1) (13 deaths)Pepin - 1 casePierce - 51 casesPolk - 36 cases (+2) (1 death)Portage - 51 cases (+12)Price - 2 casesRacine - 1,952 cases (+13) (51 deaths)Richland - 14 cases (4 deaths)Rock - 724 cases (+10) (21 deaths)Rusk - 5 casesSauk - 84 cases (3 deaths)Sawyer - 9 casesShawano - 60 casesSheboygan - 120 cases (+2) (4 deaths) (+1)St. Croix - 108 cases (+1)Taylor - 2 casesTrempealeau - 44 cases (+1)Vernon - 22 casesVilas - 8 casesWalworth - 456 cases (+4) (17 deaths)Washburn - 3 casesWashington - 283 cases (+2) (10 deaths)Waukesha - 842 cases (+13) (34 deaths)Waupaca - 61 cases (+3) (1 death)Waushara - 13 casesWinnebago - 457 cases (+26) (8 deaths) (+1)Wood - 13 cases (+1) (1 death)
In Michigan's Upper Peninsula, Alger and Keweenaw counties had their first confirmed coronavirus cases. Only Ontonagon County in the northwestern part of the peninsula hasn't had a confirmed case.
Michigan's Upper PeninsulaAlger - 1 case (+1)Baraga - 1 caseChippewa - 2 casesDelta - 17 cases (2 deaths)Dickinson - 6 cases (2 deaths)Gogebic - 5 cases (1 death)Houghton - 8 cases (+1)Iron - 2 casesKeweenaw - 1 case (+1)Luce - 3 casesMackinac - 8 casesMarquette - 59 cases (11 deaths)Menominee - 9 casesOntonagon - 0 casesSchoolcraft - 4 cases
SymptomsThe Centers for Disease Control and Prevention identified these as possible symptoms of COVID-19:
PreventionThe coronavirus is a new, or "novel," virus. Nobody has a natural immunity to it. Children and teens seem to recover best from the virus. Older people and those with underlying health conditions (heart disease, diabetes, lung disease) are considered at high risk, according to the CDC. Precautions are also needed around people with developing or weakened immune systems.
To help prevent the spread of the virus:
